Peptide Science Basics: Evidence-First Education on Peptides and Health

A new kind of peptide story emerged in late 2025 and has continued building through 2026: peptides designed not by studying natural biology, but by AI systems generating entirely novel amino acid sequences from scratch. One company reported its AI engine designed more than 5,000 novel candidates targeting a single receptor in 72 hours. That's a genuinely new category worth understanding, and it's also easy to overstate. This piece explains what "AI-designed peptide" actually

Interest in peptide-based hair treatments has a clear, traceable driver in 2026: the explosion in GLP-1 drug use has come with a documented side effect of hair loss for some users, and that's pushing a wave of new searches toward peptide-based regrowth options. This piece separates what's actually causing that hair loss, what peptide treatments have real supporting data, and what's still marketing riding on the broader "peptides fix everything" wave. Key Takeaways A UCSF stud

Multiple industry market reports published within days of each other in August 2026 all flagged the same thing: oral peptide delivery is growing faster than the broader peptide market containing it. That's a real trend worth explaining, but the reason it's taken this long to become one is itself the story. Peptides are proteins, and the digestive system's entire job is to break proteins apart. This piece covers what's actually been solved, what's still marketing ahead of the

A specific claim has been circulating in peptide-marketing content: that retatrutide produces meaningfully better results for women than for men, cited with precise-sounding numbers. When a claim comes with numbers that specific, it should be traceable to a real source. This one isn't, at least not to any source Eli Lilly or independent medical reporting has actually published. Here's what the actual disclosed trial data shows, and what it doesn't. Key Takeaways A specific cl

Search for menopause hormone optimization in 2026 and peptides show up constantly, usually listed alongside bioidentical estrogen, progesterone, and testosterone as if they belong to the same evidence tier. They don't. This piece audits what's actually being bundled into these programs, peptide by peptide, and checks each one against what's actually been established for it. Key Takeaways A 2026 compounding pharmacy resource listing “popular compounded medicines for hormone op

The FDA's July 2026 vote on peptide compounding wasn't about menopause at all, but menopause and midlife hormone specialists have started translating it for their own patients anyway, and some of that translation has been more careful than others. This piece walks through what the vote actually covered, what a menopause-focused clinician got right when she explained it to her own audience, and why "the FDA is opening up peptide access" is not the same claim as "the FDA review

Peptide therapy marketing aimed at women, and specifically at menopause and midlife, has expanded rapidly in 2026, with specialty clinics now publishing menopause-specific peptide guides and "best peptides for women over 50" lists. Much of this content bundles together compounds with wildly different evidence bases as though they were interchangeable. This piece works through what's actually documented for women specifically, including the one clear win in the human data, the

Self-injecting peptides has moved from a niche biohacking practice to a much more mainstream habit in 2026, and health authorities, medical associations, and Reddit communities are all documenting the same pattern: most of the real-world harm isn't coming from the peptides' pharmacology, it's coming from preparation and injection mistakes. This piece walks through what's actually going wrong, based on current clinical guidance and firsthand accounts, rather than theoretical r

Retatrutide is one of the most-searched peptide-related terms of 2026, and for good reason: Eli Lilly's investigational "triple agonist" has posted some of the largest weight-loss results ever reported in a Phase 3 program, while a parallel gray market has emerged selling unapproved versions online as a "research peptide." Those are two very different products with two very different evidence bases, and conflating them is the single biggest source of confusion in current cove

KPV is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that has shown anti-inflammatory effects in laboratory and animal research—but it has not been established as safe or effective for any use in human clinical trials. Interest is growing because KPV is commonly discussed for gut and skin inflammation and because an FDA advisory committee considered it for the federal compounding list in July 2026. Key Takeaways KPV stands for lysine-proline-

Key Takeaways Semax and Selank are synthetic peptides developed in Russia decades ago and have been used there in approved clinical formulations, but neither is FDA-approved for any indication in the United States. Semax's most-documented mechanism is upregulating brain-derived neurotrophic factor (BDNF), a protein tied to neuron growth, survival, and synaptic plasticity; Selank's most-studied mechanism is modulating the GABA system, the brain's primary calming pathway. The s

Key Takeaways GHK-Cu is a naturally occurring copper-binding tripeptide with one of the largest bodies of published research among ‘longevity’ peptides, including decades of work on collagen synthesis, wound healing, and antioxidant activity. Topical GHK-Cu (often listed as ‘copper tripeptide-1’ on ingredient labels) is regulated as a cosmetic ingredient in the U.S. and is widely used in commercial serums and creams without requiring FDA pre-approval. Injectable GHK-Cu is a c

Clinical biohacking is going mainstream in 2026. Here’s what current longevity research actually shows about peptides—and what’s still unproven. Key Takeaways Biohacking is shifting in 2026 from an elite, unregulated subculture toward evidence-based, physician-guided "clinical biohacking"—a convergence of longevity science, functional medicine, and preventive care. Peptides are one of the most discussed tools in this shift, but the evidence base varies enormously by peptide:

Peptides are widely discussed for longevity and athletic performance, but the evidence base is far thinner than most marketing suggests. Most of the striking results—lifespan extension, dramatic muscle gains—come from animal or cell studies, not controlled human trials. This overview separates what current 2026 research actually supports from what remains speculative. Key Takeaways Peptides are short amino acid chains that influence cell signaling, hormone release, and tissue